SAGE Therapeutics (SAGE) Tops Q1 EPS by 70c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Sage Therapeutics Announces First Quarter 2020 Financial Results and Highlights Pipeline and Business Progress
May 7, 2020 4:01 PM EDTExpected initiation of three new short-term zuranolone clinical studies in 2020, with the potential for three distinct indications
April restructuring to advance corporate strategy and pipeline expected to result in approximate annualized cost savings of $170M, with significant portion related to ZULRESSO commercial and G&A support
Progress continues in neurology and neuropsychiatry franchises with planned initiation of Phase 2 clinical trials of SAGE-324 in 1H and SAGE-718 in 2H, 2020
Mike Cloonan elevated to chief operating officer
Conference call today at 4:30... More
